Pharmacogenomics Services Market - GLOBAL:2022

Market Report Coverage :
Start Year : 2021 - Forecast Year : 2031 - Start Value : $5,366.1 Million in 2021 - Forecast Value : $9,346.8 Million by 2031 - CAGR % : 0.06%
Description :
Market Report Coverage - Pharmacogenomics Services

Market Segmentation

• Service - Genotyping, SNP Identification, Pharmacogenetic Testing, and Other Services
• Technology - Polymerase Chain Reaction (PCR), Microarray, Sequencing, and Other Technologies
• Application - Oncology, Infectious Disease, Neurology/Psychiatry, Cardiovascular, and Other Applications
• End User - Research Organizations, Pharmaceutical Companies, Diagnostic Centers, and Other End Users

Regional Segmentation

• North America - U.S. and Canada
• Europe - Germany, U.K., France, Italy, Spain, Demark, Netherlands, and Rest-of-Europe
• Asia-Pacific - Japan, China, Australia, India, Singapore, and Rest-of-Asia-Pacific
• Latin America - Brazil, Mexico, and Rest-of-Latin America
• Rest-of-the-World

Market Growth Drivers

• Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
• Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
• Increasing Rate of Adverse Drug Reaction
• Surge in Usage of Pharmacogenomics for Drug Discovery and Development

Market Challenges

• Lack of Use of Available Data for Drug Development Initiatives
• Lack of High Complexity Testing Centers
• Difficulties in Detecting Gene Variation Affecting Drug Response
• Regulatory Challenges for Direct-to-Consumer (DTC) Pharmacogenomics Companies

Market Opportunities

• Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
• Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
• Rise of Direct-to-Consumer (DTC) Testing Services

Key Companies Profiled

Abbott Laboratories, Admera Health, LLC, Mesa Laboratories, Inc., Dynamic DNA Laboratories, F. Hoffmann-La Roche Ltd., geneOmbio Technologies Pvt Ltd., Exact Sciences Corporation, Illumina, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., OmeCare, QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., Precipio, 23andMe, Inc., OneOme, LLC, DiaCarta, Inc., OPKO Health

Key Questions Answered in this Report:

• How are pharmacogenomics services revolutionizing clinical diagnostics and translational research?
• What are the major market drivers, challenges, and opportunities in the global pharmacogenomics services market?
• What are the underlying structures resulting in the emerging trends within the global pharmacogenomics services market?
• How did the COVID-19 pandemic impact the global pharmacogenomics services ecosystem?
• What are key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of pharmacogenomics services?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Service (genotyping, SNP identification, pharmacogenetic testing, and other services)
o Technology (polymerase chain reaction, microarray, sequencing, and other technologies)
o Application (oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications)
o End user (research organizations, pharmaceutical companies, diagnostic centers, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the pharmacogenomics services companies in the region of their operation?
• Who are the leading players with significant offerings in the global pharmacogenomics services market?
• Which companies are anticipated to be highly disruptive in the future, and why?

Market Overview

Our healthcare experts have found the pharmacogenomics services industry to be one of the most rapidly evolving and dynamic markets. The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development.

Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Furthermore, companies focus on developing pharmacogenomic tests based on advanced molecular assay technologies, which is expected to further support physicians in offering better informed clinical decisions. The development of advanced pharmacogenomic tests also enables the research community to establish effective strategies for discovering novel biomarkers associated with various diseases, which could be harnessed to develop targeted therapies.

Within the research report, the market is segmented on the basis of service, technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the prevalence associated with cancer, infectious diseases, and cardiovascular diseases, worldwide has created a buzz among the biotechnology companies to further invest in developing novel pharmacogenomic tests based on molecular technologies for supporting physicians to offer precision care. Due to the expansive service portfolio and massive global presence, Laboratory Corporation of America Holdings has been the leading player in the pharmacogenomics services ecosystem.

On the basis of region, North America holds the largest share of the pharmacogenomics services market due to the presence of market leaders such as Laboratory Corporation of America Holdings, Illumina, Inc., Thermo Fisher Scientific Inc., and Quest Diagnostics Incorporated in the U.S., coupled with the significant adoption of high-fidelity pharmacogenomic tests for drug discovery and biomarker research. Further, rising fund infusions by the federal organizations coupled with increasing investments for pharmacogenomics development are some of the prominent underlying factors supporting the growth of the North America pharmacogenomics services market. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031. This is majorly attributed to the underlying factors such as an increase in healthcare awareness, a steady economy leading to a higher focus on research, and the growth in the adoption of pharmacogenomic tests, among others.
Countries Covered :
North America
U.S.
Canada
Europe
Germany
Italy
France
U.K.
Spain
Denmark
Netherlands
Rest-of-Europe
Asia-Pacific
China
India
Singapore
Japan
Australia
Rest-of-Asia-Pacific
Latin America
Brazil
Mexico
Rest-of-Latin America (RoLA)
Rest-of-the-World
Keywords :
Pharmacogenomics Market, PGx Market, Pharmacogenomics Services Market, Pharmacogenomics Services Industry, Pharmacogenomics Services Report, Pharmacogenomics Services Market Forecasts, Pharmacogenomics Services Market Trends, Pharmacogenomics Services Market Companies, Pharmacogenomics Services Market Analysis, Pharmacogenomics Services Industry Analysis, What is Pharmacogenomics Services, Pharmacogenomics Services Definition, Pharmacogenomics Services Market Competitive Landscape, Pharmacogenomics Services Market Drivers, Pharmacogenomics Services Market Segments, Pharmacogenomics Services Market Outlook, Pharmacogenomics Services Market Opportunity, Pharmacogenomics Services Market Growth, Pharmacogenomics Services Market Share, Pharmacogenomics Services Market Size, North America Pharmacogenomics Services Market, Europe Pharmacogenomics Services Market, Latin America Pharmacogenomics Services Market
Press Release :
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 5.71% during the forecast period 2021-2031.

The comprehensive study of the global pharmacogenomics services market by BIS Research extensively covers the following:

• Market numbers on micro segments influencing the market
• More than 200 products present in the market
• Over 20 brands were evaluated
• Market share analysis for more than 15 product categories
• End-user preference data for over 20 end users
• Detailed global and regional market share analysis, including the scrutiny of more than 16 countries
• Study of data of more than 19 companies

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 100+ products.

BIS Research study indicates that the increasing prevalence of infectious diseases and various types of cancer, rising adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development, among others, are fueling the growth of the global pharmacogenomics services market.

The market intelligence report by BIS research also highlights opportunities existing in the market, such as massive scope for adoption of pharmacogenomics in emerging nations, technological advancements in molecular techniques for pharmacogenomic diagnostic tests, and rise of direct-to-consumer (DTC) testing services.

To gain a holistic view of the market, data from different market segments has been analyzed minutely. These segments include service, application, technology, end user, and region. The service and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analyses of preferred pharmacogenomics services products and services. Pertaining to the market segmentation, the service segment is segmented into genotyping, single nucleotide polymorphism (SNP) identification, pharmacogenetic testing, and other services.

Additionally, the application segment of the market has been segmented into oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications.
Further, the technology segment has been broadly classified into polymerase chain reaction (PCR), microarray, sequencing, and other technologies. Finally, the end-user segment has been segmented into research organizations, pharmaceutical companies, diagnostic centers, and other end users.

Emphasizing the dominance of the North America region in the global pharmacogenomics services market in 2021 and 2031, Nitish Singh, Analyst – BIS Research, states, " In North America, several emerging and legacy companies are focusing on expanding their respective pharmacogenomics services portfolio for clinical and research use. Additionally, emerging companies are massively investing in developing advanced pharmacogenomic tests based on molecular assay technologies, particularly for clinical applications to enable precision medicine. Moreover, the significant uptake of research activities on drug and biomarker discovery, increase in prevalence of cancer, cardiovascular, and infectious disease, and rise in awareness among patients regarding targeted therapeutics, among others, promoted the adoption of pharmacogenomic tests by end users.”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 19 leading companies, market participants, and vendors. Key players profiled in the report include Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., QIAGEN N.V., Illumina, Inc., Quest Diagnostics Incorporated, Abbott Laboratories, Mesa Laboratories, Inc., Admera Health, LLC, geneOmbio Technologies Pvt Ltd., Dynamic DNA Laboratories, Exact Sciences Corporation, Myriad Genetics, Inc., OMECare, Precipio, 23andMe, Inc., OneOme, LLC, OPKO Health, and DiaCarta, Inc.

The study also offers strategic recommendations to help organizations track various pharmacogenetic tests changing market dynamics. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

• Pharmacogenomic test developers and providers that are involved in the development and commercialization of pharmacogenomics services.
• Emerging companies in the field of pharmacogenomics services to assess the market situation.

How can market intelligence on Pharmacogenomics services add value to an organization’s decision-making process?

• Aids in pharmacogenomic test development
• Helps in targeting a segment for launching new tests
• Offers go to market access strategies
• Supports in diversifying the portfolio basis risk and progression of underlying technologies
• Helps in analyzing specifications
• Aids in understanding the end-user landscape
• Helps in gaining holistic views pertaining to regions and understanding the market potential of the countries.
• Supports in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companies

Insightful Questions Covered to Enable Companies to Take Strategic Decisions

• How are pharmacogenomics services revolutionizing clinical diagnostics and translational research?
• What are the major market drivers, challenges, and opportunities in the global pharmacogenomics services market?
• What are the underlying structures resulting in the emerging trends within the global pharmacogenomics services market?
• How did the COVID-19 pandemic impact the global pharmacogenomics services ecosystem?
• What are key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of pharmacogenomics services?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Service (genotyping, SNP identification, pharmacogenetic testing, and other services)
o Technology (polymerase chain reaction, microarray, sequencing, and other technologies)
o Application (oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications)
o End user (research organizations, pharmaceutical companies, diagnostic centers, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the pharmacogenomics services companies in the region of their operation?
• Who are the leading players with significant offerings in the global pharmacogenomics services market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Companies Mentioned :
Abbott Laboratories
Admera Health, LLC
Mesa Laboratories, Inc.
Dynamic DNA Laboratories
F. Hoffmann-La Roche Ltd.
geneOmbio Technologies Pvt Ltd.
Exact Sciences Corporation
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
OmeCare
QIAGEN N.V.
Quest Diagnostics Incorporated
Thermo Fisher Scientific Inc.
Precipio
23andMe, Inc.
OneOme, LLC
DiaCarta, Inc.
OPKO Health
Press Release :
The global pharmacogenomics services market is projected to reach $9,346.8 million by 2031, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 5.71% during the forecast period 2021-2031.

The comprehensive study of the global pharmacogenomics services market by BIS Research extensively covers the following:

• Market numbers on micro segments influencing the market
• More than 200 products present in the market
• Over 20 brands were evaluated
• Market share analysis for more than 15 product categories
• End-user preference data for over 20 end users
• Detailed global and regional market share analysis, including the scrutiny of more than 16 countries
• Study of data of more than 19 companies

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of 100+ products.

BIS Research study indicates that the increasing prevalence of infectious diseases and various types of cancer, rising adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development, among others, are fueling the growth of the global pharmacogenomics services market.

The market intelligence report by BIS research also highlights opportunities existing in the market, such as massive scope for adoption of pharmacogenomics in emerging nations, technological advancements in molecular techniques for pharmacogenomic diagnostic tests, and rise of direct-to-consumer (DTC) testing services.

To gain a holistic view of the market, data from different market segments has been analyzed minutely. These segments include service, application, technology, end user, and region. The service and ecosystem analysis of the global market include data analysis on the satisfaction level of different pricing analyses of preferred pharmacogenomics services products and services. Pertaining to the market segmentation, the service segment is segmented into genotyping, single nucleotide polymorphism (SNP) identification, pharmacogenetic testing, and other services.

Additionally, the application segment of the market has been segmented into oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications.
Further, the technology segment has been broadly classified into polymerase chain reaction (PCR), microarray, sequencing, and other technologies. Finally, the end-user segment has been segmented into research organizations, pharmaceutical companies, diagnostic centers, and other end users.

Emphasizing the dominance of the North America region in the global pharmacogenomics services market in 2021 and 2031, Nitish Singh, Analyst – BIS Research, states, " In North America, several emerging and legacy companies are focusing on expanding their respective pharmacogenomics services portfolio for clinical and research use. Additionally, emerging companies are massively investing in developing advanced pharmacogenomic tests based on molecular assay technologies, particularly for clinical applications to enable precision medicine. Moreover, the significant uptake of research activities on drug and biomarker discovery, increase in prevalence of cancer, cardiovascular, and infectious disease, and rise in awareness among patients regarding targeted therapeutics, among others, promoted the adoption of pharmacogenomic tests by end users.”

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 19 leading companies, market participants, and vendors. Key players profiled in the report include Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., QIAGEN N.V., Illumina, Inc., Quest Diagnostics Incorporated, Abbott Laboratories, Mesa Laboratories, Inc., Admera Health, LLC, geneOmbio Technologies Pvt Ltd., Dynamic DNA Laboratories, Exact Sciences Corporation, Myriad Genetics, Inc., OMECare, Precipio, 23andMe, Inc., OneOme, LLC, OPKO Health, and DiaCarta, Inc.

The study also offers strategic recommendations to help organizations track various pharmacogenetic tests changing market dynamics. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

Who should buy this report?

• Pharmacogenomic test developers and providers that are involved in the development and commercialization of pharmacogenomics services.
• Emerging companies in the field of pharmacogenomics services to assess the market situation.

How can market intelligence on Pharmacogenomics services add value to an organization’s decision-making process?

• Aids in pharmacogenomic test development
• Helps in targeting a segment for launching new tests
• Offers go to market access strategies
• Supports in diversifying the portfolio basis risk and progression of underlying technologies
• Helps in analyzing specifications
• Aids in understanding the end-user landscape
• Helps in gaining holistic views pertaining to regions and understanding the market potential of the countries.
• Supports in analyzing the competitive landscape to gain an understanding of the business strategies incorporated by the companies

Insightful Questions Covered to Enable Companies to Take Strategic Decisions

• How are pharmacogenomics services revolutionizing clinical diagnostics and translational research?
• What are the major market drivers, challenges, and opportunities in the global pharmacogenomics services market?
• What are the underlying structures resulting in the emerging trends within the global pharmacogenomics services market?
• How did the COVID-19 pandemic impact the global pharmacogenomics services ecosystem?
• What are key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of pharmacogenomics services?
• What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
o Service (genotyping, SNP identification, pharmacogenetic testing, and other services)
o Technology (polymerase chain reaction, microarray, sequencing, and other technologies)
o Application (oncology, infectious disease, neurology/psychiatry, cardiovascular, and other applications)
o End user (research organizations, pharmaceutical companies, diagnostic centers, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
• What are the growth opportunities for the pharmacogenomics services companies in the region of their operation?
• Who are the leading players with significant offerings in the global pharmacogenomics services market?
• Which companies are anticipated to be highly disruptive in the future, and why?
Headline :
Global Pharmacogenomics Services Market to Reach $9,346.8 Million by 2031
Table of Contents :
1 Market
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Scope
1.2.1 Scope of the Study
1.2.2 Key Questions Answered in the Report
1.3 Research Methodology
1.3.1 Global Pharmacogenomics Services Market: Research Methodology
1.3.2 Data Sources
1.3.2.1 Primary Data Sources
1.3.2.2 Secondary Data Sources
1.3.3 Market Estimation Model
1.3.4 Criteria for Company Profiling
1.4 Market Overview
1.4.1 Market Definition
1.4.2 Emerging Applications of Pharmacogenomics Services
1.4.3 Significant Services in the Pharmacogenomics Ecosystem
1.4.4 Market Footprint and Growth Potential, $Million, 2020-2031
1.4.5 Impact of COVID-19 on the Global Pharmacogenomics Services Market
2 Industry Analysis
2.1 Overview
2.2 Legal Requirements and Framework in the U.S.
2.3 Legal Requirements and Framework in Europe
2.3.1 China
2.3.2 Japan
3 Market Dynamics
3.1 Overview
3.2 Iceberg Analysis - Global Pharmacogenomics Services Market
3.3 Impact Analysis
3.4 Market Drivers
3.4.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer Globally
3.4.2 Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
3.4.3 Increasing Rate of Adverse Drug Reaction
3.4.4 Surge in Usage of Pharmacogenomics for Drug Discovery and Development
3.5 Market Restraints
3.5.1 Lack of Use of Available Data for Drug Development Initiatives
3.5.2 Lack of High Complexity Testing Centers
3.5.3 Difficulties in Detecting Gene Variation Affecting Drug Response
3.5.4 Regulatory Challenges for Direct-to-Consumer (DTC) Pharmacogenomics Companies
3.6 Market Opportunities
3.6.1 Massive Scope for Adoption of Pharmacogenomics in Emerging Nations
3.6.2 Technological Advancements in Molecular Techniques for Pharmacogenomic Diagnostic Tests
3.6.3 Rise of Direct-to-Consumer (DTC) Testing Services
4 Competitive Landscape
4.1 Overview
4.2 Synergistic Activities
4.3 Product Approvals
4.4 Product Launches
4.5 Business Expansion, Funding, and Reimbursement Activities
4.6 Mergers and Acquisitions
4.7 Market Share Analysis, 2019 and 2020
4.8 Growth Share Analysis
4.8.1 Growth Share Analysis (by Company)
4.8.2 Growth Share Analysis (by Technology)
4.8.3 Growth Share Analysis (by Application)
5 Service, $Million, 2020-2031
5.1 Overview
5.2 Genotyping
5.3 SNP Identification
5.4 Pharmacogenetic Testing
5.5 Other Services
6 Technology, $Million, 2020 – 2031
6.1 Overview
6.2 Polymerase Chain Reaction (PCR)
6.3 Microarray
6.4 Sequencing
6.5 Other Technologies
7 Application, $Million, 2020–2031
7.1 Overview
7.2 Oncology
7.3 Infectious Diseases
7.4 Neurology/Psychiatry
7.5 Cardiovascular
7.6 Other Applications
8 End User, $Million, 2020-2031
8.1 Overview
8.2 Research Organizations
8.2.1 Global Pharmacogenomics Services Market (Research Organizations, by Service)
8.3 Pharmaceutical Companies
8.3.1 Global Pharmacogenomics Services Market (Pharmaceutical Companies, by Service)
8.4 Diagnostic Centers
8.4.1 Global Pharmacogenomics Services Market (Diagnostic Centers, by Service)
8.5 Other End Users
8.5.1 Global Pharmacogenomics Services Market (Other End Users, by Service)
9 Region, $Million, 2020-2031
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.2.3 North America Pharmacogenomics Services Market (by Application)
9.2.4 North America Pharmacogenomics Services Market (by Service)
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Italy
9.3.5 Spain
9.3.6 Denmark
9.3.7 Netherlands
9.3.8 Rest-of-Europe
9.3.9 Europe Pharmacogenomics Services Market (by Application)
9.3.10 Europe Pharmacogenomics Services Market (by Service)
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 Australia
9.4.4 India
9.4.5 Singapore
9.4.6 Rest-of-Asia-Pacific (RoAPAC)
9.4.7 Asia-Pacific Pharmacogenomics Services Market (by Application)
9.4.8 Asia-Pacific Pharmacogenomics Services Market (by Service)
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest-of-Latin America (RoLA)
9.5.4 Latin America Pharmacogenomics Services Market (by Application)
9.5.5 Latin America Pharmacogenomics Services Market (by Service)
9.6 Rest-of-the-World
9.6.1 Rest-of-the-World Pharmacogenomics Services Market (by Application)
9.6.2 Rest-of-the-World Pharmacogenomics Services Market (by Service)
10 Company Profiles
10.1 Overview
10.2 Abbott Laboratories
10.2.1 Company Overview
10.2.2 Role of Abbott Laboratories in the Global Pharmacogenomics Services Market
10.2.3 Financials
10.2.4 Key Insights about Financial Health of the Company
10.2.5 SWOT Analysis
10.3 Admera Health, LLC
10.3.1 Company Overview
10.3.2 Role of Admera Health, LLC in the Global Pharmacogenomics Services Market
10.3.3 SWOT Analysis
10.4 Mesa Laboratories, Inc.
10.4.1 Company Overview
10.4.2 Role of Mesa Laboratories, Inc. in the Global Pharmacogenomics Services Market
10.4.3 Financials
10.4.4 Key Insights about Financial Health of the Company
10.4.5 SWOT Analysis
10.5 Dynamic DNA Laboratories
10.5.1 Company Overview
10.5.2 Role of Dynamic DNA Laboratories in the Global Pharmacogenomics Services Market
10.5.3 SWOT Analysis
10.6 F. Hoffmann-La Roche Ltd.
10.6.1 Company Overview
10.6.2 Role of F. Hoffmann La-Roche Ltd. in the Global Pharmacogenomics Services Market
10.6.3 Financials
10.6.4 Key Insights about Financial Health of the Company
10.6.5 SWOT Analysis
10.7 geneOmbio Technologies Pvt Ltd.
10.7.1 Company Overview
10.7.2 Role of geneOmbio Technologies Pvt Ltd. in the Global Pharmacogenomics Services Market
10.7.3 SWOT Analysis
10.8 Exact Sciences Corporation
10.8.1 Company Overview
10.8.2 Role of Exact Sciences Corporation in the Global Pharmacogenomics Services Market
10.8.3 Financials
10.8.4 Key Insights about Financial Health of the Company
10.8.5 SWOT Analysis
10.9 Illumina, Inc.
10.9.1 Company Overview
10.9.2 Role of Illumina, Inc. in the Global Pharmacogenomics Services Market
10.9.3 Financials
10.9.4 Key Insights about Financial Health of the Company
10.9.5 SWOT Analysis
10.1 Laboratory Corporation of America Holdings
10.10.1 Company Overview
10.10.2 Role of Laboratory Corporation of America Holdings in the Global Pharmacogenomics Services Market
10.10.3 Financials
10.10.4 SWOT Analysis
10.11 Myriad Genetics, Inc.
10.11.1 Company Overview
10.11.2 Role of Myriad Genetics, Inc. in the Global Pharmacogenomics Services Market
10.11.3 Financials
10.11.4 Key Insights about Financial Health of the Company
10.11.5 SWOT Analysis
10.12 OmeCare
10.12.1 Company Overview
10.12.2 Role of OmeCare in the Global Pharmacogenomics Services Market
10.12.3 SWOT Analysis
10.13 QIAGEN N.V.
10.13.1 Company Overview
10.13.2 Role of QIAGEN N.V. in the Global Pharmacogenomics Services Market
10.13.3 Financials
10.13.4 Key Insights about Financial Health of the Company
10.13.5 SWOT Analysis
10.14 Quest Diagnostics Incorporated
10.14.1 Company Overview
10.14.2 Role of Quest Diagnostics Incorporated in the Global Pharmacogenomics Services Market
10.14.3 Financials
10.14.4 SWOT Analysis
10.15 Thermo Fisher Scientific Inc.
10.15.1 Company Overview
10.15.2 Role of Thermo Fisher Scientific Inc. in the Global Pharmacogenomics Services Market
10.15.3 Financials
10.15.4 Key Insights about Financial Health of the Company
10.15.5 SWOT Analysis
10.16 Precipio
10.16.1 Company Overview
10.16.2 Role of Precipio in the Global Pharmacogenomics Services Market
10.16.3 Financials
10.16.4 SWOT Analysis
10.17 23andMe, Inc.
10.17.1 Company Overview
10.17.2 Role of 23andMe, Inc. in the Global Pharmacogenomics Services Market
10.17.3 SWOT Analysis
10.18 OneOme, LLC
10.18.1 Company Overview
10.18.2 Role of OneOme, LLC in the Global Pharmacogenomics Services Market
10.18.3 SWOT Analysis
10.19 DiaCarta, Inc.
10.19.1 Company Overview
10.19.2 Role of DiaCarta, Inc. in the Global Pharmacogenomics Services Market
10.19.3 SWOT Analysis
10.2 OPKO Health
10.20.1 Company Overview
10.20.2 Role of OPKO Health in the Global Pharmacogenomics Services Market
10.20.3 Financials
10.20.2 Key Insights About Financial Health of the Company
10.20.3 SWOT Analysis
List of Figures
Figure 1: Estimates for Global Healthcare Market, 2018 and 2020
Figure 2: Impact Analysis of Market Drivers and Challenges on the Global Pharmacogenomics Services Market
Figure 3: Global Pharmacogenomics Services Market (by Service), $Million, 2020 and 2031
Figure 4: Global Pharmacogenomics Services Market (by Application), $Million, 2020 and 2031
Figure 5: Global Pharmacogenomics Services Market (by Technology), $Million, 2020 and 2031
Figure 6: Global Pharmacogenomics Services Market (by End User), $Million, 2020 and 2031
Figure 7: Global Pharmacogenomics Services Market Snapshot
Figure 8: Global Pharmacogenomics Services Market Segmentation
Figure 9: Global Pharmacogenomics Services Market: Methodology
Figure 10: Primary Research Methodology
Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
Figure 12: Top-Down Approach (Segment-Wise Analysis)
Figure 13: Global Pharmacogenomics Services Market, $Million, 2020-2031
Figure 14: Global Pharmacogenomics Services Market: COVID-19 Impact Analysis
Figure 15: Components Considered for Clinical Evidence as per the IVDR
Figure 16: Process of Medical Device Designation by the MHLW and PMDA
Figure 17: Number of Deaths by Top 18 Infectious Diseases, 2015
Figure 18: Number of Deaths by Different Forms of Cancer, Million, 2020
Figure 19: Benefits of Multiplexing Reactions
Figure 20: Share of Key Developments and Strategies, January 2018-December 2021
Figure 21: Share of Synergistic Activities (by Company), January 2018-December 2021
Figure 22: Share of Product Approvals (by Company), January 2018-December 2021
Figure 23: Number of Product Launches (by Company), January 2018-December 2021
Figure 24: Share of Business Expansion, Funding, and Reimbursement Activities (by Company), January 2018-December 2021
Figure 25: Share of Mergers and Acquisitions (by Company), January 2018-December 2021
Figure 26: Market Share Analysis for the Global Pharmacogenomics Services Market, $Million, 2019 and 2020
Figure 27: Growth Share Analysis for the Global Pharmacogenomics Services Market (by Company), 2020
Figure 28: Growth Share Analysis for the Global Pharmacogenomics Services Market (by Technology), 2020-2031
Figure 29: Growth Share Analysis for the Global Pharmacogenomics Services Market (by Application), 2020-2031
Figure 30: Global Pharmacogenomics Services Market (by Service)
Figure 31: Global Pharmacogenomics Services Market (by Service), 2020 and 2031
Figure 32: Global Pharmacogenomics Services Market (by Genotyping), $Million, 2020-2031
Figure 33: Global Pharmacogenomics Services Market (by SNP Identification), $Million, 2020-2031
Figure 34: Global Pharmacogenomics Services Market (by Pharmacogenetic Testing), $Million, 2020-2031
Figure 35: Global Pharmacogenomics Services Market (by Other Services), $Million, 2020-2031
Figure 36: Global Pharmacogenomics Services Market (by Technology)
Figure 37: Global Pharmacogenomics Services Market (by Technology), $Million, 2020 and 2031
Figure 38: Global Pharmacogenomics Services Market (by PCR), $Million, 2020-2031
Figure 39: Global Pharmacogenomics Services Market (by Microarray), $Million, 2020-2031
Figure 40: Evolution of Sequencing for Molecular Diagnostics
Figure 41: Global Pharmacogenomics Services Market (by Sequencing), $Million, 2020-2031
Figure 42: Global Pharmacogenomics Services Market (by Other Technologies), $Million, 2020-2031
Figure 43: Global Pharmacogenomics Services Market (by Application)
Figure 44: Global Pharmacogenomics Services Market (by Application), 2020 and 2031
Figure 45: Global Pharmacogenomics Services Market (by Oncology), $Million, 2020-2031
Figure 46: Global Pharmacogenomics Services Market (by Infectious Diseases), $Million, 2020-2031
Figure 47: Global Pharmacogenomics Services Market (by Neurology/Psychiatry), $Million, 2020-2031
Figure 48: Global Pharmacogenomics Services Market (by Cardiovascular), $Million, 2020-2031
Figure 49: Global Pharmacogenomics Services Market (by Other Applications), $Million, 2020-2031
Figure 50: Global Pharmacogenomics Services Market (by End User)
Figure 51: Global Pharmacogenomics Services Market (by End User), $Million, 2020–2031
Figure 52: Global Pharmacogenomics Services Market (by Research Organizations), $Million, 2020-2031
Figure 53: Global Pharmacogenomics Services Market (Research Organizations by Service), Share, 2020 and 2031
Figure 54: Global Pharmacogenomics Services Market (by Pharmaceutical Companies), $Million, 2020-2031
Figure 55: Global Pharmacogenomics Services Market (Pharmaceutical Companies, by Service), Share, 2020 and 2031
Figure 56: Global Pharmacogenomics Services Market (by Diagnostic Centers), $Million, 2020-2031
Figure 57: Global Pharmacogenomics Services Market (Diagnostic Centers, by Service), Share, 2020 and 2031
Figure 58: Global Pharmacogenomics Services Market (by Other End Users), $Million, 2020-2031
Figure 59: Global Pharmacogenomics Services Market (Other End Users, by Service), Share, 2020 and 2031
Figure 60: Global Pharmacogenomics Services Market Snapshot (by Region)
Figure 61: Global Pharmacogenomics Services Market (by Region), $Million, 2020-2031
Figure 62: Global Pharmacogenomics Services Market (by Region), 2020 and 2031
Figure 63: North America Pharmacogenomics Services Market, $Million, 2020-2031
Figure 64: North America Pharmacogenomics Services Market (by Country), $Million, 2020-2031
Figure 65: U.S. Pharmacogenomics Services Market, $Million, 2020-2031
Figure 66: Canada Pharmacogenomics Services Market, $Million, 2020-2031
Figure 67: North America Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
Figure 68: North America Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
Figure 69: Europe Pharmacogenomics Services Market, $Million, 2020-2031
Figure 70: Europe Pharmacogenomics Services Market (by Country), $Million, 2020–2031
Figure 71: Germany Pharmacogenomics Services Market, $Million, 2020-2031
Figure 72: U.K. Pharmacogenomics Services Market, $Million, 2020-2031
Figure 73: France Pharmacogenomics Services Market, $Million, 2020-2031
Figure 74: Italy Pharmacogenomics Services Market, $Million, 2020-2031
Figure 75: Spain Pharmacogenomics Services Market, $Million, 2020-2031
Figure 76: Denmark Pharmacogenomics Services Market, $Million, 2020-2031
Figure 77: Netherlands Pharmacogenomics Services Market, $Million, 2020-2031
Figure 78: Rest-of-Europe Pharmacogenomics Services Market, $Million, 2020-2031
Figure 79: Europe Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
Figure 80: Europe Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
Figure 81: Asia-Pacific Pharmacogenomics Services Market, $Million, 2020-2031
Figure 82: APAC Pharmacogenomics Services Market (by Country), $Million, 2020-2031
Figure 83: Japan Pharmacogenomics Services Market, $Million, 2020-2031
Figure 84: China Pharmacogenomics Services Market, $Million, 2020-2031
Figure 85: Australia Pharmacogenomics Services Market, $Million, 2020-2031
Figure 86: India Pharmacogenomics Services Market, $Million, 2020-2031
Figure 87: Singapore Pharmacogenomics Services Market, $Million, 2020-2031
Figure 88: Rest-of-Asia-Pacific Pharmacogenomics Services Market, $Million, 2020-2031
Figure 89: Asia-Pacific Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
Figure 90: Asia-Pacific Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
Figure 91: Latin America Pharmacogenomics Services Market, $Million, 2020-2031
Figure 92: Latin America Pharmacogenomics Services Market (by Country), $Million, 2020-2031
Figure 93: Brazil Pharmacogenomics Services Market, $Million, 2020-2031
Figure 94: Mexico Pharmacogenomics Services Market, $Million, 2020-2031
Figure 95: Rest-of-Latin America Pharmacogenomics Services Market, $Million, 2020-2031
Figure 96: Latin America Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
Figure 97: Latin America Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
Figure 98: Rest-of-the-World Pharmacogenomics Services Market, $Million, 2020-2031
Figure 99: Rest-of-the-World Pharmacogenomics Services Market (by Application), Share, 2020 and 2031
Figure 100: Rest-of-the-World Pharmacogenomics Services Market (by Service), Share, 2020 and 2031
Figure 101: Total Number of Companies Profiled
Figure 102: Abbott Laboratories: Portfolio
Figure 103: Abbott Laboratories: Overall Financials, $Million, 2018-2020
Figure 104: Abbott Laboratories: Revenue (by Segment), $Million, 2018-2020
Figure 105: Abbott Laboratories: Revenue (by Region), $Million, 2018-2020
Figure 106: Abbott Laboratories: R&D Expenditure, $Million, 2018-2020
Figure 107: Abbott Laboratories: SWOT Analysis
Figure 108: Admera Health, LLC: Portfolio
Figure 109: Admera Health, LLC: SWOT Analysis
Figure 110: Mesa Laboratories, Inc.: Portfolio
Figure 111: Mesa Laboratories, Inc.: Overall Financials, $Million, 2018-2020
Figure 112: Mesa Laboratories, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 113: Mesa Laboratories, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 114: Mesa Laboratories, Inc.: SWOT Analysis
Figure 115: Dynamic DNA Laboratories: Portfolio
Figure 116: Dynamic DNA Laboratories: SWOT Analysis
Figure 117: F. Hoffmann-La Roche Ltd.: Portfolio
Figure 118: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2018-2020
Figure 119: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2018-2020
Figure 120: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2018-2020
Figure 121: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2018-2020
Figure 122: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 123: geneOmbio Technologies Pvt Ltd.: Portfolio
Figure 124: geneOmbio Technologies Pvt Ltd.: SWOT Analysis
Figure 125: Exact Sciences Corporation: Portfolio
Figure 126: Exact Sciences Corporation: Overall Financials, $Million, 2018-2020
Figure 127: Exact Sciences Corporation: Revenue (by Segment), $Million, 2018-2020
Figure 128: Exact Sciences Corporation: Revenue (by Region), $Million, 2018-2020
Figure 129: Exact Sciences Corporation: R&D Expenditure, $Million, 2018-2020
Figure 130: Exact Sciences Corporation: SWOT Analysis
Figure 131: Illumina, Inc.: Portfolio
Figure 132: Illumina, Inc.: Overall Financials, $Million, 2018-2020
Figure 133: Illumina, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 134: Illumina, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 135: Illumina, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 136: Illumina, Inc.: SWOT Analysis
Figure 137: Laboratory Corporation of America Holdings: Portfolio
Figure 138: Laboratory Corporation of America Holdings: Overall Financials, $Million, 2018-2020
Figure 139: Laboratory Corporation of America Holdings: Revenue (by Segment), $Million, 2018-2020
Figure 140: Laboratory Corporation of America Holdings: Revenue (by Region), $Million, 2018-2020
Figure 141: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 142: Myriad Genetics, Inc.: Portfolio
Figure 143: Myriad Genetics, Inc.: Overall Financials, $Million, 2018-2020
Figure 144: Myriad Genetics, Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 145: Myriad Genetics, Inc.: Revenue (by Region), $Million, 2018-2020
Figure 146: Myriad Genetics, Inc.: R&D Expenditure, $Million, 2018-2020
Figure 147: Myriad Genetics, Inc.: SWOT Analysis
Figure 148: OmeCare: Portfolio
Figure 149: OmeCare: SWOT Analysis
Figure 150: QIAGEN N.V.: Portfolio
Figure 151: QIAGEN N.V.: Overall Financials, $Million, 2018-2020
Figure 152: QIAGEN N.V.: Revenue (by Segment), $Million, 2018-2020
Figure 153: QIAGEN N.V.: Revenue (by Region), $Million, 2018-2020
Figure 154: QIAGEN N.V.: R&D Expenditure, $Million, 2018-2020
Figure 155: QIAGEN N.V.: SWOT Analysis
Figure 156: Quest Diagnostics Incorporated: Portfolio
Figure 157: Quest Diagnostics Incorporated: Overall Financials, $Million, 2018-2020
Figure 158: Quest Diagnostics Incorporated: Revenue (by Segment), $Million, 2018-2020
Figure 159: Quest Diagnostics Incorporated: SWOT Analysis
Figure 160: Thermo Fisher Scientific Inc.: Portfolio
Figure 161: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2018-2020
Figure 162: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2018-2020
Figure 163: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2018-2020
Figure 164: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2018-2020
Figure 165: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 166: Precipio: Portfolio
Figure 167: Precipio: Overall Financials, $Million, 2018-2020
Figure 168: Precipio: SWOT Analysis
Figure 169: 23andMe, Inc.: Portfolio
Figure 170: 23andMe, Inc.: SWOT Analysis
Figure 171: OneOme, LLC: Portfolio
Figure 172: OneOme, LLC: SWOT Analysis
Figure 173: DiaCarta, Inc.: Portfolio
Figure 174: DiaCarta, Inc.: SWOT Analysis
Figure 175: OPKO Health: Portfolio
Figure 176: OPKO Health: Overall Financials, $Million, 2018-2020
Figure 177: OPKO Health: Revenue (by Segment), $Million, 2018–2020
Figure 178: OPKO Health: Revenue (by Region), $Million, 2018-2020
Figure 179: OPKO Health: R&D Expenditure, $Million, 2018-2020
Figure 180: OPKO Health: SWOT Analysis
List of Tables
Table 1: Classification Rules of IVDs under the IVDR
Table 2: Registration Criteria for IVD Medical Devices as per the NMPA
Table 3: Likert Scale
Table 4: Impact Analysis of Market Drivers
Table 5: Impact Analysis of Market Restraints
Table 6: Examples of Adverse Drug Reactions
Table 7: North America: Market Dynamics
Table 8: Europe: Market Dynamics
Table 9: APAC: Market Dynamics
Table 10: Latin America: Market Dynamics